Literature DB >> 27940551

Management of alcohol misuse in patients with liver diseases.

Jennifer L Peng1, Milan Prakash Patel1, Breann McGee1, Tiebing Liang1, Kristina Chandler1, Sucharat Tayarachakul1,2, Sean O'Connor3,4, Suthat Liangpunsakul1,4,5.   

Abstract

Excessive alcohol use not only causes alcoholic liver disease (ALD) but also increases the risk of liver-related mortality in patients who already have other chronic liver diseases. Screening for alcohol misuse or alcohol use disorder (AUD) among patients with underlying liver disease is essential. This clinical review covers what is known about ALD, the impact of alcohol in patients with underlying liver diseases, current management of alcohol misuse and AUD, and the management of alcohol misuse and AUD specifically in patients with liver diseases. Several treatment options for alcohol misuse and AUD exist such as psychosocial intervention and behavioral and pharmacological therapies. The strategies used in the treatment of alcohol misuse and AUD are still applicable in those who consume alcohol and have underlying liver disease. However, certain medications still need to be carefully used due to potentially worsening already compromised liver function. Screening of ongoing alcohol use in subjects with liver disease is important, and prompt intervention is needed to prevent the associated morbidity and mortality from the detrimental effects of continued alcohol use on underlying liver disease. Considering alcoholism is a complex disease, probably a multidisciplinary approach combining psychotherapy and comprehensive medical care will be the most effective. Future research could focus on identifying additional treatment options for addressing the psychotherapy component since the self-determination and will to quit drinking alcohol can play such a crucial role in promoting abstinence.
Copyright © 2017 American Federation for Medical Research.

Entities:  

Keywords:  Alcohol Drinking; Disease Management; Liver Diseases

Mesh:

Substances:

Year:  2016        PMID: 27940551      PMCID: PMC5495189          DOI: 10.1136/jim-2016-000254

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  67 in total

1.  EFFECTS OF PROLONGED ETHANOL INTAKE: PRODUCTION OF FATTY LIVER DESPITE ADEQUATE DIETS.

Authors:  C S LIEBER; D P JONES; L M DECARLI
Journal:  J Clin Invest       Date:  1965-06       Impact factor: 14.808

Review 2.  Baclofen: a new drug for the treatment of alcohol dependence.

Authors:  G Addolorato; L Leggio; R Agabio; G Colombo; G Gasbarrini
Journal:  Int J Clin Pract       Date:  2006-08       Impact factor: 2.503

3.  Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis.

Authors:  T Yamanaka; K Shiraki; S Nakazaawa; H Okano; T Ito; M Deguchi; K Takase; T Nakano
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

4.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.

Authors:  L Leggio; A Ferrulli; A Zambon; F Caputo; G A Kenna; R M Swift; G Addolorato
Journal:  Addict Behav       Date:  2011-12-27       Impact factor: 3.913

6.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

7.  Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis.

Authors:  G Corrao; S Aricò
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

8.  Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis.

Authors:  Linda M Fletcher; Jeannette L Dixon; David M Purdie; Lawrie W Powell; Darrell H G Crawford
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

9.  Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence.

Authors:  F Pessione; M J Ramond; L Peters; B N Pham; P Batel; B Rueff; D C Valla
Journal:  Liver Int       Date:  2003-02       Impact factor: 5.828

Review 10.  Hemochromatosis and alcoholic liver disease.

Authors:  Linda M Fletcher; Lawrie W Powell
Journal:  Alcohol       Date:  2003-06       Impact factor: 2.405

View more
  4 in total

1.  Inhibition of the Inflammasome Signaling Cascade Reduces Alcohol Consumption in Female But Not Male Mice.

Authors:  Patrick P Lowe; Yeonhee Cho; David Tornai; Sahin Coban; Donna Catalano; Gyongyi Szabo
Journal:  Alcohol Clin Exp Res       Date:  2020-01-09       Impact factor: 3.455

2.  Attacking Alcohol-Related Liver Disease by Taxing Alcohol Sales.

Authors:  Elliot B Tapper; Neehar D Parikh; Suthat Liangpunsakul
Journal:  Alcohol Clin Exp Res       Date:  2020-12-13       Impact factor: 3.455

Review 3.  Epidemiology of Alcohol-Associated Liver Disease.

Authors:  Sen Han; Zhihong Yang; Ting Zhang; Jing Ma; Kristina Chandler; Suthat Liangpunsakul
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.265

4.  Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.

Authors:  Jovan Julien; Turgay Ayer; Elliot B Tapper; Carolina Barbosa; William N Dowd; Jagpreet Chhatwal
Journal:  Hepatology       Date:  2022-01-24       Impact factor: 17.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.